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Proteomic discovery and verification 
of serum amyloid A as a predictor marker 
of patients at risk of post-stroke infection: a pilot 
study
L. Azurmendi1†, V. Lapierre‑Fetaud1†, J. Schneider2, J. Montaner3, M. Katan2† and Jean‑Charles Sanchez1*†
Abstract 
Background: Post‑stroke infections occur in 20–36% of stroke patients and are associated with high morbidity and 
mortality rates. Early identification of patients at risk of developing an infection could improve care via an earlier treat‑
ment leading to a better outcome. We used proteomic tools in order to discover biomarkers able to stratify patients at 
risk of post‑stroke infection.
Methods: The post hoc analysis of a prospective cohort study including 40 ischemic stroke patients included 21 
infected and 19 non‑infected participants. A quantitative, isobaric labeling, proteomic strategy was applied to the 
plasma samples of 5 infected and 5 non‑infected patients in order to highlight any significantly modulated proteins. 
A parallel reaction monitoring (PRM) assay was applied to 20 additional patients (10 infected and 10 non‑infected) to 
verify discovery results. The most promising protein was pre‑validated using an ELISA immunoassay on 40 patients 
and at different time points after stroke onset.
Results: Tandem mass analysis identified 266 proteins, of which only serum amyloid A (SAA1/2) was significantly 
(p = 0.007) regulated between the two groups of patients. This acute‑phase protein appeared to be 2.2 times more 
abundant in infected patients than in non‑infected ones. These results were verified and validated using PRM and 
ELISA immunoassays, which showed that infected patients had significantly higher concentrations of SAA1/2 than 
non‑infected patients at hospital admission, but also at 1, 3, and 5 days after admission.
Conclusions: The present study demonstrated that SAA1/2 is a promising predictor, at hospital admission, of stroke 
patients at risk of developing an infection. Further large, multicenter validation studies are needed to confirm these 
results. If confirmed, SAA1/2 concentrations could be used to identify the patients most at risk of post‑stroke infec‑
tions and therefore implement treatments more rapidly, thus reducing mortality.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Stroke is a serious medical condition produced by brain 
cell death. It occurs when there is a lack of blood flow 
to the brain (~80% of cases) or a hemorrhage affecting 
the brain or its surroundings (20%). Every year, around 
15 million people will suffer a stroke, leading to 6 million 
deaths and 5 million disabled patients [1–3]. Around 40% 
of patients die within the first weeks following the stroke 
[4, 5]. Non-modifiable factors, such as the severity of the 
stroke or the age of the patient, are highly correlated with 
mortality [6, 7]. However, one-third of deaths result from 
potentially preventable stroke-associated complications. 
Nosocomial infection, particularly bacterial pneumonia, is 
the most common complication after stroke, with an inci-
dence of 5–22% [8–10]. Despite the intensive care given 
to these patients, infection rates remain elevated and are 
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associated with bad functional outcome and mortality [11]. 
The high incidence of infection is likely to be a result of an 
impaired immune function. The patient’s reduced ability 
combat bacteria is a consequence of the initial brain dam-
age [12, 13]. Therefore, the early identification of patients 
who might be prone to developing an infection after stroke 
is a necessary step towards better hospital management, 
more rapid implementation of treatments, and improved 
long-term patient outcomes [13, 14].
In clinical practice, the diagnosis of post-stroke infec-
tion is a challenging one as there has been no satisfactory 
concordance between different studies. The most widely 
studied markers of post-stroke infection—procalcitonin 
(PCT), C-reactive protein (CRP), and white blood cells 
(WBC)—have only shown moderate predictive value, 
and their levels do not increase early enough to be of help 
before the infection is clinically apparent [15, 16]. Clinical 
signs such as older age, fever, severe stroke, or dysphagia, 
among others, have been linked to post-stroke associ-
ated pneumonia [17]. Nevertheless, they are not specific 
enough to act as individual markers. Using a combination 
of these markers with clinical scales such as the A2DS2, 
AIS-APS, and ISAN [17–19] have not been applied rou-
tinely in clinical practice. The gold standard for diagnos-
ing an infection is the result from a bacterial culture, yet 
this may take 2 days. All of these reasons can lead to anti-
biotic treatment being started too late, with the unfortu-
nate associated consequences. There is thus evidence of a 
need for a reliable early biomarker [20].
The present study aimed to use proteomic approaches 
to find a biomarker that could be tested for at hospital 
admission in order to identify patients at risk of develop-
ing a post-stroke infection. To do this, we investigated the 
plasma proteomes of infected and non-infected patients, 
using isobaric labeling methods. After selecting SAA1/2 
as the most promising protein, parallel reaction monitor-
ing (PRM) and the enzyme-linked immunosorbent assays 
(ELISA) confirmed its ability to predict which patients 
were at risk of infection after a stroke.
Methods
Study design and setting
We performed a post hoc analysis of a prospective cohort 
study which included 40 ischemic stroke patients (Clini-
calTrials.gov.NCT00390962) who had been hospitalized 
consecutively at the University Hospital of Basel (Swit-
zerland) between November 2006 and November 2007. 
The study protocol was conducted according to the prin-
ciples expressed in the Declaration of Helsinki and with 
the approval of the local ethics committee. Before enrol-
ment, informed consent was obtained from patients, 
their relatives, or their legal guardians.
Clinical protocol
Comprehensive information on the assessment of the 
study participants’ demographic and vascular risk fac-
tors has been published previously [15]. Briefly, ischemic 
stroke was defined according to the World Health Organ-
ization criteria [21]. A detailed history was obtained for 
vascular risk factors, vital signs, and relevant comorbidi-
ties as assessed using the Charlson Comorbidity Index 
(CCI) medication taken prior to the stroke. Neurological 
deficits were estimated using the National Institutes of 
Health Stroke Scale (NIHSS). Patients underwent the fol-
lowing standardized diagnostic workup: brain computer 
tomography (CT) and/or magnetic resonance imaging, 
long-term electrocardiography, echocardiography, and 
neurosonographic imaging of the extracranial and intrac-
ranial arteries. Stroke etiology was determined according 
to the TOAST (Trial of Org 10172 in Acute Stroke Treat-
ment) classification criteria, which distinguish large-
artery arteriosclerosis, cardio embolism, small-artery 
occlusion, other etiologies, and undetermined etiologies 
[22].
Definition of stroke‑associated Infections
Stroke-associated infection (SAI) was defined as any 
infection occurring within the first 5  days after hospi-
tal admission [13]. Infections were diagnosed according 
to the U.S. Centers for Disease Control and Prevention 
(CDC) criteria [15]. We distinguished between pneumo-
nia, urinary tract infection (UTI), and other infections 
(OI). Pneumonia was diagnosed when at least one symp-
tom from each of the two following symptom groups was 
present: (1) abnormal respiratory examination, pulmo-
nary infiltrates in chest X-rays; (2) productive cough with 
purulent sputum, positive microbiological cultures from 
the lower respiratory tract or blood cultures.
Diagnosis of a UTI required two of the following cri-
teria to be met: fever (≥38.0  °C), urine sample positive 
for nitrite, leukocyturia (≥40/µL), or significant bacte-
riuria (≥104/mL of an uropathogen). OI were diagnosed 
if white blood cell count was ≥11,000/mL and CRP was 
≥10 mg/L or temperature was ≥38.0 °C and an infectious 
manifestation was present. The treating physician made 
the diagnosis of pneumonia during hospitalization. This 
was then validated post hoc using charts.
The time point of diagnosis was taken to be the begin-
ning of clinical symptoms which led to the diagnostic 
workup and resulted in the diagnosis of infection. In 
order to exclude any acute infections that had preceded 
the stroke, patients with an admission temperature 
>38 °C, reporting an infection lasting up to 3 days before 
the onset of stroke, or who required mechanical intuba-
tion were not included in the study.
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Blood sample collection
Blood samples were collected from venous blood punc-
ture within the first 72  h following symptom onset and 
then 1, 3, and 5 days after admission. Blood was centri-
fuged for 30  min at 3000×g, collected in EDTA, tubes 
and stored at −80 °C.
Proteomic study
Quantitative proteomic analysis: TMT
Quantitative proteomic analyses were performed on five 
infected and five non-infected patients at hospital admis-
sion. The aim was to identify significantly regulated pro-
teins between the two groups in order to find a promising 
infection marker.
Reduction, alkylation, digestion, and TMT labeling The 
quantitative proteomic experiment used 1  µL of each 
plasma sample. These amounts were dried and reconsti-
tuted in 16.6 µL of 6 M urea in tetraethylammonium bro-
mide (TEAB) 0.1 M. The proteins were reduced by adding 
1  µL of 50  mM tris-(2-carboxyethyl) phosphine hydro-
chloride (TCEP) to each sample, and they then reacted for 
1 h at 37 °C. After the sample had cooled to room tem-
perature, the alkylation step required mixing the solution 
with 1 µL of iodoacetamide 400 mM and storage at room 
temperature for 30  min. Sixty seven  µL of TEAB 0.1  M 
were added to reduce the concentration of urea to <2 M. 
The digestion was carried out overnight at 37  °C using 
1 µg of trypsin for each 20 µg of protein. The protocol is 
detailed by Dayon et al. [23, 24].
Subsequently, each digested plasma sample was labeled 
with one of the 10  TMT reagents (Thermo Fisher Sci-
entific, Waltham, USA). Infected patients’ samples were 
labeled with TMTs 127n, 128n, 129n, 130n, and 131n. 
Non-infected patients’ samples were labeled with TMTs 
126, 127c, 128c, 129c, and 130c. To calculate experimen-
tal error, 1 µg of β-lactoglobulin was spiked in each sam-
ple. All the samples were pooled, desalted using a C18 
Macro SpinColumn, and dried in a speed-vacuum.
Off‑gel electrophoresis (OGE) OGE separation was car-
ried out using an Agilent 3100 Off-Gel fractionator, as per 
the manufacturer’s instructions. Previously dried sam-
ples were reconstituted using the OGE solution and then 
focused using an immobilized pH gradient (IPG) dry strip 
(13 cm, pH 3–10) [23]. After OGE, samples were desalted 
using a C18 Micro SpinColumn, dried in the speed-vac-
uum, and stored at −20 °C until analysis.
LC–MS/MS A Q-Exactive Plus mass spectrometer 
(ThermoFisher, San Jose, CA), coupled with nanoflow 
high-pressure liquid chromatography (HPLC), was used 
to analyze the OGE fractions, as previously described [25]. 
Briefly, peptides reconstituted using 5% CAN, 0.1% FA, 
were trapped in a 5 µm 200 Å Magic C18 AQ (Michrom) 
0.1 × 20 mm pre-column and separated in a 5 µm 100 Å 
Magic C18 AQ (Michrom) 0.75 × 150 mm column with 
a gravity-pulled emitter. Both columns were made in-
house. The analytical separation ran for 65  min using a 
gradient of  H2O/FA 99.9/0.1% (solvent A) and  CH3CN/
FA 99.9/0.1% (solvent B). The gradient ran at a flow rate 
of 220 nL/min as follows: 0–1 min 95% A and 5% B, then 
to 65% A and 35% B at 55 min, and 20% A and 80% B at 
65 min. For the MS survey scans, OT resolution was set 
to 60,000 and the ion population was set to 5 × 105 with 
an m/z window from 400 to 2000. A maximum of three 
precursors were selected for both collision-induced dis-
sociation (CID) in the LTQ and higher-energy collisional 
dissociation (HCD) with analysis in the OT. For MS/MS 
in the LTQ, the ion population was set to 7 × 103 (isola-
tion width of 2 m/z), whereas for MS/MS detection in the 
OT, it was set to 2 × 105 (isolation width of 2.5 m/z), with 
a resolution of 7500, a first mass at m/z = 100, and a maxi-
mum injection time of 750 ms. The normalized collisional 
energies were set to 35% for CID and 60% for HCD.
Protein identification MS data were processed using 
EasyProtConv. Peak lists were obtained using the 12 
OGE fractions and the combination of HCD-CID raw 
data peak lists were generated. Afterwards, these data 
were submitted to an EasyProt software platform (ver-
sion 2.3, build 718) that uses Phenyx software (GeneBio, 
Geneva, Switzerland) for protein identification. The 
protein search was made using the Uniprot/Swiss-Prot 
database (2014–10, 669903) [26], applying the follow-
ing search criteria: Homo  sapiens taxonomy, oxidized 
methionine (as the variable modification), and cysteine 
carbamethylation,  TMT10 lysine, and  TMT10 amino-ter-
minus (as the fixed modifications). Trypsin was selected 
as the proteolytic enzyme, allowing one missed cleavage. 
Parent-ion tolerance was set to 10 ppm and the accuracy 
of fragment ions to 0.6 Da. Only proteins with a less than 
1% false discovery rate (FDR) and at least two different 
unique peptides were selected for further analysis [27]. A 
minimum peptide length of 6 amino acids was used.
Protein quantification used the Isobar R package [28]. 
The manufacturer’s isotopic distribution data was used 
to correct the isotopic impurities of  TMT10 reporter-ion 
intensities. The equal median intensity method was used 
to normalize the reporter intensities. Peptides which 
did not present reporter intensities were not quantified. 
The infection/no infection ratio was calculated for each 
peptide, combining the reporter-ion intensities between 
infected patient channels (127n, 128n, 129n, 130n, and 
131n) and non-infected patient channels (126, 127c, 
128c, 129c, and 130c). To test the ratio’s accuracy and 
biological significance, technical and biological variability 
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were calculated for each protein ratio. A ratio p value and 
sample p value were calculated for each variable. Further-
more, only proteins with a cut-off threshold value higher 
than 1.5 or lower than 0.67 were considered [29–31].
SAA1/2 PRM analysis
Parallel reaction monitoring (PRM) analysis was per-
formed on ten infected and ten non-infected plasma 
samples using a Q-Exactive Plus mass spectrometer 
(ThermoFisher), as previously described [32]. The aim 
was to verify the discovery results.
Each sample was loaded into a PepMap precolumn 
(2  cm  ×  75  µm i.d., C18, 3  µm, and 100  Å pore size). 
Subsequent separation was performed in a PepMap col-
umn (50 cm × 75 µm i.d., C18, 2 µm, 100 Å pore size). A 
mixture of mobile A and B phases was used for peptide 
elution. The phase A solvent was composed of 0.1% (v/v) 
formic acid (Biosolve) and HPLC-grade water (Romil); 
the phase B solvent was composed of 0.1% (v/v) formic 
acid in HPLC-grade acetonitrile (Romil). To perform 
the separation, a linear gradient of 5–35% solvent B at 
250 nL/min for 60 min was set and it was followed by a 
washing step (35–90% of solvent B for 10 min).
Three masses were targeted (doubly and triply charged 
ions), corresponding to total SAA, but also specifically to 
SAA1 and SAA2. The selection of the different peptides 
was performed considering two different criteria: a previ-
ous SAA PRM study and the results of our quantitative 
proteomic analysis [32]. The three peptides selected in 
this way were tryptic peptides associated to each isoform.
This inclusion list triggered targeted scans at a resolv-
ing power of 70,000, with an isolation width of 1  Th 
around the m/z of interest, an AGC target of 1 × 106, a 
maximum injection time of 100  ms, and a normalized 
collision energy of 27% in a higher-energy c-trap disso-
ciation (HCD) cell.
Data analysis Data were analyzed using the targeted 
MS/MS feature available in Skyline v3.5 software [33]. 
In order to confirm the identity of the peptides, a data 
dependent acquisition spectral library of annotated refer-
ence MS/MS spectra was created from the two pools of 
plasma samples composed of infected and non-infected 
patients. Peptides were quantified by extracting the peak 
areas of accurate fragment ions (<6 ppm), and they were 
then integrated across the peptides’ elution profiles. For 
each peptide, transition peak areas were normalized by 
the average of the sum of the transition peak areas for all 
the peptides across the runs.
SAA1/2 ELISA measurement
The Vascular Injury Panel-I electrochemiluminescence 
(ECL) assay was used to determine the levels of SAA1/2 
in 40 stroke patients, as per the manufacturer’s instruc-
tions (Meso Scale Discovery, Gaithersburg, MD). Each 
plasma sample was diluted 1:1000 with using sample dil-
uent provided by the kit. An ECL detection system using 
multi-array technology (SECTOR Imager 2400, Meso 
Scale Discovery) was used to determine analyte concen-
trations. Samples were measured in a single detection.
Statistical analyses
Statistical analyses were carried out using SPSS software 
(v21, SPSS Inc., Chicago, IL). Analytes were not normally 
distributed, so the Mann–Whitney U-test was used to 
compare the two unpaired groups. Fisher’s exact test and 
the Chi squared test were used to assess whether patients 
with and without infection were significantly different 
according to their gender, medical history, clinical data, 
laboratory values, lesion size, or TOAST. All statistical 
tests were two-tailed, and a p value <0.05 was considered 
statistically significant.
Multivariate analyses were performed to assess the 
associations between variables. The presence/absence 
of infection was set as the dependent variable, and SAA, 
CRP, WBC, and NIHSS were set as confounders. The 
model was validated using the bootstrap method. Cat-
egorical data were dichotomized according to the criteria 
in the table of demographic characteristics. Longitudinal 
data were also dichotomized according to the best cut-off 
obtained from area under the receiver operating charac-
teristic (ROC) curve (AUC) analysis.
Results
Baseline population characteristics
Of 40 consecutively enrolled ischemic stroke patients, 21 
developed an infection within 5 days of stroke onset (day 
4 was the median day of infection development after the 
cerebrovascular event). Mean patient age was 79  years 
old (IQR: 70–82  years) and 55% of patients were men. 
Patients with severe strokes, resulting in higher NIHSS 
values at hospital admission, were more prone to devel-
oping an infection than patients with minor strokes. 
Other factors, such as hypertension, diabetes mellitus, 
or smoking, did not significantly affect the development 
of an infection. Nevertheless, according to the modi-
fied Rankin Scale, patient outcome appeared to be sig-
nificantly affected by the development of an infection, as 
most of the patients with a poor outcome had developed 
an infection during their hospital stay.
At hospital admission, levels of WBC and CRP were 
within the normal range in both groups, with no sig-
nificant differences found between infected and non-
infected patients. Patients’ demographic characteristics 
are summarized in Table 1. 
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Proteomic results
In order to find a biomarker able to distinguish, at hospi-
tal admission, which patients will and will not develop a 
post-stroke infection, the proteomes of five infected and 
five non-infected stroke patients were compared using 
quantitative proteomic analysis. Applying the criteria of 
a maximum of 1% FDR and at least two unique peptides, 
266 proteins were quantified (Additional file 1: Table 1). 
Of all the proteins, serum amyloid A1 appeared to be the 
only significantly (p = 0.007) regulated protein between 
the two groups of patients, with a ratio of 2.2 after Bon-
ferroni correction.
To verify the results obtained by the  TMT10 plex dur-
ing the discovery phase, a further PRM analysis was per-
formed on a new batch of patients. Consequently, we 
targeted three transitions of the tryptic SFFSFLGEAFD-
GAR peptide in 10 infected and 10 non-infected 
patients. This peptide is common to all the different 
isoforms of acute-phase SAA. By measuring its con-
centration, therefore, we were sure to measure the total 
amount SAA present in blood and not only that of one of 
the different described isoforms. As shown in Fig. 1, the 
concentration of SFFSFLGEAFDGAR was significantly 
higher (p  <  0.001) in infected patients than in non-
infected ones, confirming that there was a clear over-
production of SAA in patients who went on to develop 
an infection.
Different SAA isoforms for infection development
Further PRM analyses were performed on the same 20 
patients in order to evaluate whether either of the acute 
phase isoforms (SAA1 and SAA2) had a more significant 
effect on infection and inflammatory processes. The high 
sequence-similarity between the SAA1 and SAA2 iso-
forms prevented an evaluation of their effects using clas-
sic ELISAs. The present study measured three transitions 
in the FFGHGAEDSLADQAANEWGR peptide (unique 
to SAA1) and GPGGAWAAEVISNAR peptide (unique to 
SAA2) across 10 infected and 10 non-infected patients. 
As Additional file 2: Fig. 1 shows, both peptides were sig-
nificantly (p < 0.001) more abundant in infected patients 
than in non-infected ones.
Table 1 Baseline data
All patients No infection Infection p value
(n = 40) (n = 19) (n = 21)
Demographic data
 Age, median (IQR) 79.2 (70.4–82) 78.3 (74–80.5) 80.4 (69.5–83) 0.78
 Female sex, n (%) 18 (45) 9 (47.4) 9 (42.9) 1
Medical history, n (%)
 Hypertension 31 (77.5) 12 (63.2) 19 (90.5) 0.06
 Atrial fibrillation 9 (22.5) 3 (15.8) 6 (28.6) 0.17
 Current smoking 11 (27.5) 5 (26.3) 6 (28.6) 0.64
 Diabetes mellitus 7 (17.5) 4 (21.1) 3 (14.3) 0.69
 Coronary heart disease 10 (25) 4 (21.1) 6 (28.6) 0.72
 Previous stroke 11 (27.5) 5 (26.3) 6 (28.6) 1
Clinical data, median (IQR)
 NIHSS at admission 5.5 (2–12) 3 (2–7) 12 (4–14) 0.01
Laboratory values, median (IQR)
 WBC (g/l) 8.6 (6.8–10.1) 7.7 (6.2–9.3) 9.3 (7.4–11.2) 0.14
 CRP (mg/l) 3.6 (3–9.1) 3.6 (3–6.8) 4.8 (3–17.4) 0.22
Lesion size on MR,  DWIb
 Small (1–10 mm3) 23 (27.5) 13 (68.4) 10 (47.6) 0.47
 Medium (10–100 mm3) 8 (20) 3 (15.8) 5 (23.8) 0.75
 Large (>100 mm3) 1 (2.5) 0 (0) 1 (4.8) 0.69
TOAST
 Large vessel stroke 8 (20) 3 (15.8) 0.69
 Cardioembolic stroke 8 (20) 4 (21.1) 1
 Microangipathic stroke 14 (35) 5 (26.3) 0.33
 Other 0 (0) 0 (0)
 Unknown 10 (25) 7 (36.8) 0.15
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Kinetics of serum amyloid A1/2
Serum amyloid A1/2 plasma concentrations were subse-
quently measured in a new group of 21 infected and 19 
non-infected patients in order to validate the previous 
proteomic results. Concentrations of this acute-phase 
reactant molecule were measured at hospital admission 
and at 1, 3, and 5  days after hospitalization, using an 
SAA1/2 ELISA assay. Initially, analyses were performed 
separately in those patients used for the discovery step 
and in those used for the verification/validation step. As 
Additional file 3: Fig. 2 shows, in both cases, SAA concen-
trations were significantly higher in patients who went on 
to develop a post-stroke infection than in those who did 
not. Subsequently, analyses were performed again when 
all the patients were evaluated together. As Fig. 2 shows, 
peptide concentrations were again significantly higher 
in infected patients than in non-infected patients, at all 
time points, particularly at 3 days (p = 0.01) and 5 days 
(p = 0.01) after stroke onset.
SAA measurements were evaluated to distinguish 
between the two groups of patients at D0, D1, D3, and D5. 
As Table 2 shows, the accuracy of SAA measurements in 
distinguishing which patients went on to develop an infec-
tion and which did not reached values of 73.2% (cut-off: 
14.2  µg/mL) and 77.1% (cut-off: 8.8  µg/mL) at hospital 
admission and 1  day after, respectively. Three days after 
hospitalization, the AUC of SAA was slightly better, reach-
ing a value of 80.7% (cut-off: 21.4 µg/mL), and 5 days after 
hospitalization, the AUC was 76.7% (cut-off: 87.7 µg/mL).
To evaluate the capacity of SAA1/2 measurement to 
rule-in patients at risk of infection, we set specificity (SP) 
at between 90 and 100%. At hospital admission, with a 
94.7% SP, SAA measurement reached 42.9% sensitivity 
(SE) and a partial AUC of 2.5% (Table  2). Three days 
after hospitalization, SP reached 100%, SE was 33.3%, 
and the partial AUC was 3.6% (Table  2). All the AUC 
and pAUC curves obtained at the different time points 
are represented in Fig.  3. These AUC and pAUC values 
were obtained using different cut-off concentrations cor-
responding to the best combination of SP and SE.
However, due to the high variability of the SAA con-
centrations obtained, we decided to evaluate the pos-
sibility of using a ratio based on those concentrations 
to predict the development of an infection. As Table  2 
shows, patients who went on to develop an infection 
during their hospital stay, presented with an average 2.4 
times greater concentration of SAA on D3 than on D1. 
For patients who did not become infected, average SAA 
concentrations remained very similar (ratio of 0.97), with 
no significant increase, thus suggesting that this ratio 
could be used as an indicator of patients at risk.
Multivariate analyses
Finally, we performed multivariate analyses in order to 
confirm that SAA was a promising biomarker of post-
stroke infection and to assess whether it was an inde-
pendent predictive factor. The presence of infection was 
set as the dependent variable, and the significantly regu-
lated parameters according to the patients’ demographic 
characteristics (NIHSS and SAA) were set as confound-
ers. WBC and CRP were also included in the confounder 
group because they are widely used in clinical practice. 
Fig. 2 Kinetics of SAA concentrations at hospital admission, 1, 3, and 
5 days after stroke onset. Text under Fig. 2 in PDF: SAA concentrations 
are shown by grey square for infected patients and by blue square for 
non‑infected patients. Comparisons between the two groups were 
made using the Mann–Whitney U test. Asterisk significance level 
reported after the Bonferroni correction (p < 0.05)
Fig. 1 Ratio of SFFSFLGEAFDGAR peptide abundance between 
patients who went on to develop an infection and those who did 
not. The SFFSFLGEAFDGAR peptide is common to all the different 
isoforms of SAA
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As Table  3 shows, SAA was the only marker that dis-
played a relationship with the development of post-stroke 
infections, thus confirming and validating the possibil-
ity of measuring SAA concentrations as a biomarker of 
infection in stroke patients.
Discussion
The present study highlighted the capacity of proteom-
ics to identify protein biomarkers that could assist in the 
detection of stroke patients at a high risk of developing 
post-stroke infection [34]. Using isobaric labeling meth-
ods, we first compared the plasma samples of five infected 
stroke patients and five non-infected stroke patients. We 
found that concentrations of serum amyloid A1 were 
overexpressed in patients who went on to develop an 
infection. This first approach was then verified using 
parallel reaction monitoring in 20 stroke patients (10 
infected and 10 non-infected). Finally, the SAA1/2 con-
centrations of 40 ischemic stroke patients were con-
firmed using ELISA kits. The results demonstrated that 
Table 2 Capacity of plasma concentrations of SAA to distinguish between patients who went on to develop an infection 
and those who did not
Day Number of patients Mean SAA concentration  
(µg/mL) ± SD
ROC curve
No infection Infection No infection Infection p value AUC (95% CI) Cut‑off SP% (95% CI) SE% (95% CI)
pAUC (95% CI) SP 90–100% (95% CI)
0 19 21 16 ± 38.4 61.8 ± 96.7 0.01 73.2 (55.9–87) 14.2 84.2 (68.4–100) 61.9 (38.1–81)
2.53 (0–6.7) 24.7 94.7 (84.2–100) 42.9 (23.8–62.02)
1 19 17 28.2 ± 62.6 57.7 ± 92.9 0.005 77.1 (60.1–92) 8.8 63.2 (42.1–84.2) 88.2 (70.6–100)
2.3 (0.6–6.5) 133.4 94.7 (84.2–100) 35.3 (11.8–58.8)
3 19 21 27.6 ± 55.2 140.9 ± 136 0.001 80.7 (66.2–93.2) 21.4 84.2 (68.4–100) 71.4 (52.4–90.5)
3.6 (1.7–7.6) 233.9 100 (100–100) 33.3 (14.3–52.4)
5 19 21 33.6 ± 66.4 137 ± 123.5 0.003 76.7 (61.2–89.7) 87.8 94.7 (84.2–100) 57.1 (38.1–76.2)
3.5 (0.5–7.6) 87.8 94.7 (84.2–100) 57.1 (38.1–76.2)
Fig. 3 ROC curves for SAA representing the ability to differentiate between patients who went on to develop an infection and those who did not, 
on the day of hospital admission (D0) and 1 day (D1), 3 days (D3), and 5 days after (D5) stroke onset
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SAA1/2 is an efficient infection-risk prediction marker in 
stroke patients.
SAA1/2 has already been described as a potential 
marker of inflammation and infection in several patho-
logical conditions, including stroke and subarachnoid 
hemorrhage, [35]. In a case-controlled study involving 54 
patients, levels of acute-phase proteins were significantly 
higher in stroke patients who developed an infection dur-
ing the month preceding a cerebrovascular event than in 
those who did not develop one. During the month fol-
lowing the stroke, concentrations of SAA started being 
significantly higher in patients who went on to develop an 
infection than in those who had only had an infection pre-
ceding the cerebrovascular event at 3 days after the onset 
of symptoms [36]. This highlighted that the acute-phase 
response was clearly related to the development of infec-
tions. In another study, of 60 patients, levels of SAA were 
significantly higher in 45 patients with stroke than in the 
15 control patients without stroke. SAA concentrations 
increased between days one and three in patients with a 
cerebral infarction complicated by an infectious inflam-
matory process [37]. These results suggested a correlation 
between the acute-phase response and the development 
of an infection. Nevertheless, to the best of our knowl-
edge, until now no one had evaluated the ability of these 
acute-phase molecules to act as predictors of infection.
In a population of 81 subarachnoid hemorrhage 
patients, SAA concentrations measured at hospital 
admission predicted which patients would develop an 
infection during their hospital stay with an accuracy of 
76% [38]. We therefore decided to perform the same anal-
ysis using ischemic stroke patients in the present study. 
As already shown, very similar results were obtained.
To the best of our knowledge, our study is the first to 
assess the predictive value of SAA concentrations while 
taking into account the time points of measurements as 
well as the diagnosis. We found that the SAA concentra-
tion was able to detect 42.9% of the stroke patients who 
had a very high certainty of going on to develop an infec-
tious complication.
Human SAA is an acute-phase protein primarily 
expressed by the liver [39]. There are four different but 
closely related genes responsible of the protein’s different 
isoforms. In humans, the production of SAA1 and SAA2 
takes place under inflammatory conditions. SAA3 is a 
pseudo-gene, and SAA4 encodes a protein that is pro-
duced constitutively [40]. Inflammatory SAA1 and SAA2 
share around 90% of their gene sequence. Due to the sim-
ilarities between both, immunoassays have been unable 
to differentiate between them [39], and studies to date 
have been unable to determine which of the isoforms is 
most associated with infectious and inflammatory pro-
cesses. In the present study, we used the PRM method 
to track each isoform and evaluate its contribution. As 
shown in Additional file 2: Fig. 1, both SAA1 and SAA2 
are related to infection development. The FFGHGAED-
SLADQAANEWGR peptide, unique to SAA1, and the 
tryptic SAA2 GPGGAWAAEVISNAR peptide appeared 
to be significantly more abundant in patients suffering 
from an infection than in patients without one.
SAA concentrations are most likely higher in stroke 
patients suffering from infections due to its role in 
attracting leukocytes and immune cells to the sites of tis-
sue damage, infection, or inflammation [41, 42]. As previ-
ously described, inflammation is an important part of the 
reactions taking place after an ischemic event. Indeed, 
blood derived leukocytes and microglia will be activated 
from minutes to hours after a cerebrovascular event [43]. 
Recruitment, activation, and adhesion of leukocytes to 
the endothelium will happen at the same time as neutro-
phils and monocytes/macrophages transmigrate into the 
location of the cerebral infarction [44]. During this pro-
cess of brain damage, the acute-phase response will also 
activate acute-phase proteins as SAA, CRP, haptoglobin, 
α1-acid glycoprotein, α1-antichymiotripsin appear 
increasingly in the blood [44].
The present study has certain limitations. (1) The 
cohort was small and its results should be validated in a 
larger cohort of patients in order to have sufficient sam-
ples for the subgroup analyses (infection, no-infection). 
(2) The study proposed SAA as a promising prognostic 
infection marker in stroke patients. Nevertheless, com-
bining SAA concentrations with other clinical scales 
(NIHSS) or scores could improve the accuracy of the 
association. Different combinations should be tested to 
evaluate the potential added value of a panel of mark-
ers. (3) Another point which remains to be investigated 
is why SAA concentrations become elevated in patients 
developing an infection much earlier than CRP does, 
for example. The present study postulated that this was 
due to its role in inflammation, but are we thus meas-
uring inflammation or are we facing a post-infection 
inflammation phenomenon? As previously reported, 
the acute-phase response is more prominent in patients 
who develop an infection during hospitalization, but 
Table 3 Multivariate analyses of  different factors predict-
ing the presence of infection
Infection
Predictors OR 95% CI p
SAA 3.68 (1.27–10.6) 0.047
CRP 0.37 (0.12–1.17) 0.09
WBC 1.24 (0.86–1.79) 0.24
NIHSS 1.18 (1.01–1.38) 0.031
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SAA concentrations were already higher when a previous 
bacterial infection was present. A detailed study should 
be performed to compare all these factors. (4) Different 
isoforms of SAA did not seem to act differently in con-
ditions of inflammation. Nevertheless, the present study 
was only able to measure one tryptic peptide from each 
isoform. Further studies should target different peptides 
corresponding to the different isotypes of each isoform 
in order to perform a give a more detailed analysis of the 
role of SAA in infected stroke patients. Finally, to trans-
late this study’s results into clinical practice, a point of 
care test should be developed in order to provide results 
in minutes and ensure better, faster patient management.
Conclusions
In a small cohort of stroke patients, we were able to demon-
strate that the concentrations of SAA1/2 measured at hospi-
tal admission could be used to predict post-stroke infection. 
Applying SAA measurement in clinical settings could dras-
tically improve patient management and, consequently, 
their associated outcomes. Further large, multicenter valida-
tion studies are needed to confirm these results.
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